Abstract Purpose of Review There is a lack of consistency among the ACC/AHA and ESC
Guidelines on the treatment of patients with lower extremity PAD to a targeted LDL-c level. A …

Peripheral artery disease (PAD) is estimated to affect approximately 8.5 million individuals in
the US above the age of 40, and is associated with significant morbidity, mortality, and …

Patients with peripheral arterial disease (PAD) are at very high risk of cardiovascular events,
but risk factor management is usually suboptimal. This Joint Task Force from the European …

Background Low-density lipoprotein cholesterol (LDL-C) is associated with heightened risk
of major adverse cardiovascular events (MACE) and major adverse limb events (MALE) in …

Highlights•Peripheral artery disease (PAD) is characterized by increased cardiovascular
risk.•Statins remain the first-line lipid-lowering therapy to treat PAD patients.•Statins …

In the past 50 years, randomized clinical trials demonstrated benefits of intensive low-
density lipoprotein–lowering therapy for people with cardiovascular disease, including in …

Background Lipid‐lowering therapy is recommended for secondary prevention in people
with coronary artery disease. It may also reduce cardiovascular events and/or local disease …

Peripheral artery disease (PAD) is a manifestation of systemic atherosclerosis and is
associated with high mortality due to cardiovascular events. As lipid-lowering therapy has …

Peripheral arterial disease (PAD) affects 12% of adult population and is increasing globally
and in India. Peripheral arterial disease when associated with atherosclerosis in two or more …

Aims This review aims to explore the current guidance and issues surrounding lipid
optimisation of patients with peripheral arterial disease (PAD). Methods A narrative review of …